论文部分内容阅读
OBJECTIVE:To further evaluate the complementary effect of Yiqi Huoxue Jiedu decoction (YHJD) on patients with advanced epithelial ovarian cancer (EOC).METHODS:All 330 enrolled participants diagnosed with stage Ⅲ c EOC were randomly divided into two groups that received YHJD or a placebo.The primary end point was health-related quality of life (HRQL) measured by the functional assessment of cancer therapy-ovary cancer (FACT-O) questionnaire.The secondary end point was progression-free survival (PFS).RESULTS:A total of 299 participants completed the trial with 153 and 146 in YHJD and control groups,respectively.After 6 months of treatment,YHJD increased physical wellbeing (PWB),functional wellbeing (FWB),additional concs (AC),and the trial outcome index (TOI) (P ＜ 0.05) by various degrees compared with the baseline.YHJD also had notable advantages over the placebo at 3 and 6 months in terms of PWB,FWB,AC (P ＜ 0.05),and TOI (P ＜ 0.01).In addition,YHJD had a significant advantage in terms of PFS compared with the placebo (21 vs 18 months,P ＜ 0.05).No adverse events were reported.CONCLUSION:YHJD is an effective and safe choice as a complementary therapy to improve HRQL and prolong PFS of stage Ⅲ c EOC patients.